Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Recursion Pharmaceuticals, Inc. Banner

Recursion Pharmaceuticals, Inc.

RXRX Stock Analysis

Page title

Section title

Breakdown
2019
2020
2021
2022
2023
Net Income
-61.879m-87.006m-186.479m-239.476m-328.066m
Depreciation & Amortization
2.489M4.442M8.405M11.756M24.402M
Change in Working Capital
408.000K30.834M-306.000k104.921M-50.257m
Operating Cash Flow
-57.042m-45.399m-158.614m-83.524m-287.780m
Capital Expenditure
-3.910m-6.735m-39.798m-37.359m-11.955m
Free Cash Flow
-60.952m-52.134m-198.412m-120.883m-300.332m
Debt Repayment
705.000K6.323M-12.798m-90.000k-766.000k
Dividends Paid
0.0000.0000.0000.0000.000
Common Stock Issued
119.705M239.812M462.901M143.711M128.093M
Common Stock Repurchased
0.0000.0000.0000.0000.000
Net Change in Cash
59.458M191.996M28.182M263.763M-157.687m